Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Fleishaker

Showing results (21-30 of 72) with videos related to

Pageof 8
Sort By:
European Journal of Clinical Pharmacology|January 1, 1996
Comparison of the pharmacokinetics of tirilazad mesylate in healthy volunteers and stable subjects with mild liver cirrhosisL K Pearson, J C Fleishaker, G R Peters
Pharmaceutical Research|May 5, 1999
Population pharmacokinetics of tirilazad: effects of weight, gender, concomitant phenytoin, and subarachnoid hemorrhageJ C Fleishaker, J Fiedler-Kelly, T H Grasela
Biopharmaceutics & Drug Disposition|March 23, 1999
Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokineticsJ C Fleishaker, M Mucci, C Pellizzoni, et al.
Journal of Clinical Pharmacology|February 1, 1993
Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: I. Single-dose administrationJ C Fleishaker, G R Peters, K S Cathcart
Journal of Pharmacokinetics and Biopharmaceutics|August 1, 1987
Mean residence time in peripheral tissueP J McNamara, J C Fleishaker, T L Hayden
Journal of Pharmaceutical Sciences|March 1, 1995
Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans--a putative measure of CYP3A inductionJ C Fleishaker, L K Pearson, G R Peters
Journal of Clinical Pharmacology|August 1, 1994
Lack of a pharmacokinetic/pharmacodynamic interaction between nimodipine and tirilazad mesylate in healthy volunteersJ C Fleishaker, L K Hulst, G R Peters
Biopharmaceutics & Drug Disposition|November 1, 1990
Effect of food on the bioavailability of adinazolam from a sustained release formulation: effect of meal timing and lack of dose dumpingJ C Fleishaker, J P Phillips, H S Lau
Pharmaceutical Research|February 1, 1994
Lack of pharmacokinetic interaction between cimetidine and tirilazad mesylateJ C Fleishaker, L K Hulst, G R Peters
Biopharmaceutics & Drug Disposition|April 9, 1998
Induction of tirilazad clearance by phenytoinJ C Fleishaker, L K Pearson, G R Peters
Pageof 8

Showing results (21-30 of 72) with videos related to

Sort By:
Pageof 8
European Journal of Clinical Pharmacology|January 1, 1996
Comparison of the pharmacokinetics of tirilazad mesylate in healthy volunteers and stable subjects with mild liver cirrhosisL K Pearson, J C Fleishaker, G R Peters
Pharmaceutical Research|May 5, 1999
Population pharmacokinetics of tirilazad: effects of weight, gender, concomitant phenytoin, and subarachnoid hemorrhageJ C Fleishaker, J Fiedler-Kelly, T H Grasela
Biopharmaceutics & Drug Disposition|March 23, 1999
Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokineticsJ C Fleishaker, M Mucci, C Pellizzoni, et al.
Journal of Clinical Pharmacology|February 1, 1993
Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: I. Single-dose administrationJ C Fleishaker, G R Peters, K S Cathcart
Journal of Pharmacokinetics and Biopharmaceutics|August 1, 1987
Mean residence time in peripheral tissueP J McNamara, J C Fleishaker, T L Hayden
Journal of Pharmaceutical Sciences|March 1, 1995
Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans--a putative measure of CYP3A inductionJ C Fleishaker, L K Pearson, G R Peters
Journal of Clinical Pharmacology|August 1, 1994
Lack of a pharmacokinetic/pharmacodynamic interaction between nimodipine and tirilazad mesylate in healthy volunteersJ C Fleishaker, L K Hulst, G R Peters
Biopharmaceutics & Drug Disposition|November 1, 1990
Effect of food on the bioavailability of adinazolam from a sustained release formulation: effect of meal timing and lack of dose dumpingJ C Fleishaker, J P Phillips, H S Lau
Pharmaceutical Research|February 1, 1994
Lack of pharmacokinetic interaction between cimetidine and tirilazad mesylateJ C Fleishaker, L K Hulst, G R Peters
Biopharmaceutics & Drug Disposition|April 9, 1998
Induction of tirilazad clearance by phenytoinJ C Fleishaker, L K Pearson, G R Peters
Pageof 8